To better stratify [177Lu]Lu-PSMA-617 RLT candidates and to support translation of new therapeutic options for patients with insufficient PSMA expression, a better understanding of tumour heterogeneity in mCRPC patients is needed. The gene discussed is FOLH1; the disease is neoplasm.